Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting Disclosure of the discovery and structure of NX-1607, the first inhibitor of CBL-B to advance into clinical studies.